Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2023 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2919 Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II Studies of Lu-Octreotate Peptide Receptor Radionuclide Therapy (LuTate PRRT) +/- Capecitabine, Temozolomide (CAPTEM) or CAPTEM Alone for Neuroendocrine Tumours (NETs

Introduction: Chemotherapy is often combined with PRTT to treat NETs of pancreatic or midgut origin (pNET/mNET) based on the principle of radiosensitization.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Pavlakis N

Authors: Pavlakis N, Ransom D, Wyld D, Sjoquist K, Asher R,

Keywords: Lutate, PRRT, chemotherapy, CAPTEM, NETs,

#2812 SILVELUL Project: Development of an New Potential Predictive Immunohistochemical Score (SPI) in Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus

Introduction: Previously our group showed the potential use of a score based on MGMT, NDRG-1 and PHLDA-3 immunohistochemistry (IHC) expression as predictor of outcome in operated PanNET (Viúdez et al. Oncotarget 2016).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Viudez A

Authors: Viudez A, Crespo G, Gómez-Dorronsoro M, Benavent M, Hernando J,

Keywords: biomarker, PHLDA3, MGMT, IHC, NDRG1, CAPTEM, everolimus,

#2247 Efficacy of Oral Chemotherapy with Capecitabine and Temozolomide (Captem) in Patients with Metastatic Neuroendocrine Tumors (NETS). A Single-Institution Experience

Introduction: CapTem chemotherapy regimen is a standard treatment for NETs but limited scientific data on its efficacy and tolerability are available

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Smiroldo V, Carnaghi C, Lania A, Bonifacio C, Pepe G,

Keywords: CapTem, metastatic neuroendocrine tumors,

#2136 Combination of Capecitabine and Temozolomide for Advanced Thymic Neuroendocrine Tumors

Introduction: In vitro data indicate that the combination of capecitabine(CAP) and temozolomide(TEM) is synergistic for induction of apoptosis in neuroendocrine tumor cell lines. It has been proven that the CAPTEM regimen is associated with an exceptionally high and durable response rate in patients with metastatic pancreatic neuroendocrine tumors. However, there is less evidence to illustrate if the CAPTEM regimen is effective for thymic neuroendorine tumors(TNET).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Tan H

Authors: Wang X, Li Y, Shi Y, Chen Y, Qiu X,

Keywords: thymic neuroendocrine tumors, capecitabine, temozolomide, progress-free survival, adverse effect,

#2041 Hepatic Tumor Burden Can be Reduced Rapidly and Effectively by Trans-Arterial Embolization Combined with Systemic Therapy in Patients with Neuroendocrine Tumor Liver Metastasis (NETLM)

Introduction: The main tumor burden of patients with neuroendocrine tumor liver metastasis is comprised by hepatic lesions.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Liu Y

Authors: Liu Y, Wang Y, Lian F, Shen L, Chen L,

Keywords: intervention, TAE, liver metastasis,

Abstract Submissions for 2024

Abstract submissions for 2024 are now closed; all submitted abstracts are currently being reviewed by the abstract reviewing committee.

 

The 21st Annual ENETS Conference in 2024 provides the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2023 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.